Anti-lap antibody variants
US11130802B2 · kind B2 · utility
0Cited by
81References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 9, 2019 |
| Grant date | Sep 28, 2021 |
| Priority date | — |
| Expiry date | Oct 9, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.